安罗替尼在肺癌治疗中的研究进展

摘要
图/表
参考文献(26)
相关文章 (15)

全文: PDF (0 KB) HTML (33 KB)
输出: BibTeX | EndNote (RIS)

摘要肺癌是最常见的恶性肿瘤之一。近年来，我国肺癌的发病率和死亡率一直位列首位。由于绝大多数肺癌发现时已属晚期，生存率低，且缺乏有效的治疗方式，故寻求新的药物以延长肺癌患者的生存时间具有更为重要的价值。随着肿瘤治疗手段的进步，由中国自主研发的抗血管生成药物安罗替尼在肺癌的治疗上已显示出良好的抗肿瘤作用，目前已应用于晚期肺癌的三线治疗。然而，目前安罗替尼在临床应用中仍存在许多问题。进一步研究安罗替尼的抗肿瘤作用机制和联合治疗模式以及预测疗效的生物标志物，可使更多的肺癌患者获益。本文就安罗替尼在肺癌治疗中的研究进展综述如下。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李莲港
	姜军

关键词 ：安罗替尼, 肺癌, 血管生成, 生物标志物, 不良事件

Abstract：Lung cancer is one of the most common malignant tumors.In recent years,incidence and mortality of lung cancer have been ranked first in China.When most lung cancers are found,they are already in the advanced stage,so the survival rate of patients is low and there is also a lack of effective treatment methods.Therefore,seeking new medication that can prolong the survival time of lung cancer patients is of more important value.As tumor treatment methods advance,the antiangiogenic drug Anlotinib developed independently by China has shown great antineoplastic effects in the treatment of lung cancer.At present,it has been applied to the third-line treatment of advanced lung cancer.However,there remain a lot of questions regarding the clinical application of Anlotinib.Further research on Anlotinib′s antineoplastic mechanism,combined treatment methods and biomarkers which predicate the efficacy can benefit more lung cancer patients.This article reviews the research advances of Anlotinib in the treatment of lung cancer.

Key words： Anlotinib Lung cancer Angiogenesis Biomarkers Adverse events

基金资助:青海省科技厅基础研究计划项目（2017-ZJ-710）

引用本文:

李莲港；姜军. 安罗替尼在肺癌治疗中的研究进展[J]. 中国当代医药, 2020, 27(2): 12-14.
LI Lian-gang； JIANG Jun. Research progress of Anlotinib in the treatment of lung cancer. 中国当代医药, 2020, 27(2): 12-14.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2020/V27/I2/12

[1]	Bray F，Ferlay J，Soerjomataram I，et al.Global cancer statistics 2018：Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin，2018，68（6）：394-424.
[2]	郑荣寿，孙可欣，张思维，等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志，2019，41（1）：19-28.
[3]	Chen W，Sun K，Zheng R，et al.Cancer incidence and mortality in China，2014[J].Chin J Cancer Res，2018，30（1）：1-12.
[4]	Syed YY.Anlotinib：First Global Approval[J].Drugs，2018，78（10）：1057-1062.
[5]	郝希山，魏于全.肿瘤学[M].北京：人民卫生出版社，2010，108-118.
[6]	Folkman J.Tumor angiogenesis：therapeutic implications[J].N Engl J Med，1971，285（21）：1182-1186.
[7]	Xie C，Wan X，Quan H，et al.Preclinical characterization of anlotinib，a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor[J].Cancer Sci，2018，109（4）：1207-1219.
[8]	Lin B，Song X，Yang D，et al.Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2，PDGFRβ and FGFR1[J].Gene，2018，654（6）：77-86.
[9]	Maryam Abbaspour Babaei，Behnam Kamalidehghan，Mohammad Saleem，et al.Receptor tyrosine kinase（c-Kit）inhibitors：a potential therapeutic target in cancer cells[J].Drug Des Devel Ther，2016，10（8）：2443-2459.
[10]	Han B，Zhou C.Efficacy and safety of sintilimab with anlotinib as first-line therapy for advanced non-small cell lung cancer[R].WCLC，2019-04-02.
[11]	安罗替尼联合多西他赛二线治疗NSCLC 临床研究一例病例分享[EB/OL].https：//e.dxy.cn/anlotinib/moment/id/367.2019.
[15]	聚焦驱动基因突变阳性NSCLC 二线治疗，安罗替尼联合AP 方案初探[EB/OL].http：//www.sohu.com/a/319644342_333130.2019.
[16]	Yang S，Zhang Z，Wang Q.Emerging therapies for small cell lung cancer[J].J Hematol Oncol，2019，12（1）：47.
[12]	Han B，Li K，Zhao Y，et al.Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer：a multicentre，randomised phase Ⅱtrial（ALTER0302）[J].Br J Cancer，2018，118（5）：654-661.
[13]	Han B，Li K，Wang Q，et al.Effect of anlotinib as a thirdline or further treatment on overall survival of patients with advanced non-small cell lung cancer：the alter 0303 phase 3 randomized clinical trial[J].JAMA oncol，2018，4（11）：1569-1575.
[14]	Wu D，Nie J，Dai L，et al.Salvage treatment with anlotinib for advanced non-small cell lung cancer[J].Thorac Cancer，2019，10（7）：1590-1596.
[17]	2019WCLC 重磅研究盘点：小细胞肺癌九大方案降临[EB/OL].http：//www.sohu.com/a/336543456_120051954.2019.
[18]	Cheng Y，Wang Q，Li K，et al.Anlotinib as third-line or further-line Treatment in relapsed SCLC：a multicentre，randomized，double-blind phase 2 trial[J].J Thorac Oncol，2018，13（10）：351-352.
[19]	杨琳.安罗替尼维持治疗广泛期小细胞肺癌的疗效及安全性观察[D].郑州：郑州大学，2019.
[20]	Liu Z，Wang J，Meng Z，et al.CD31-labeled circulating endothelial cells as predictor in anlotinib-treated non-smallcell lung cancer：analysis on alter-0303 study[J].Cancer Med，2018，7（7）：3011-3021.
[21]	Lu J，Zhong H，Chu T，et al.Role of anlotinib -induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy[J].Eur Respir J，2018，53（3）：1 801 562.
[22]	Han B，Li K，Wang Q，et al.P3.03-006 Efficiency of anlotinib as 3rd line treatment in Patients with different EGFR gene status，an exploratory subgroup analysis of alter-0303 trial[J].J Thorac oncol 2017，12（11）：2275.
[23]	Najjar F，Alammar M，Al-Massarani G，et al.Circulating endothelial cells and microparticles as diagnostic and prognostic biomarkers in small-cell lung cancer[J].Lung Cancer，2018，124（12）：23-30.
[24]	Si X，Zhang L，Wang H，et al.Quality of life results from a randomized，double-blinded，placebo-controlled，multi-center phase Ⅲtrial of anlotinib in patients with advanced nonsmall cell lung cancer[J].Lung Cancer，2018，122（3）：32-37.
[25]	Si X，Zhang L，Wang H，et al.Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer：experiences in alter-0303[J].Thorac Cancer，2019，10（3）：551-556.
[26]	Sun W，Wang Z，Chen R，et al.Influences of anlotinib on cytochrome P450 enzymes in rats using a cocktail method[J].Biomed Res Int，2017，2017（5）：3 619 723.